SynthesisThe Cochrane database of systematic reviews2006
Progesterone for preventing pre-eclampsia and its complications.
Synthesis in The Cochrane database of systematic reviews, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 6 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- The long-term effect of prenatal progesterone treatment on child development, behaviour and health: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2021Pooled it
- Antenatal interventions for preventing stillbirth, fetal loss and perinatal death: an overview of Cochrane systematic reviews.The Cochrane database of systematic reviews · 2020Pooled it
- Guided imagery for treating hypertension in pregnancy.The Cochrane database of systematic reviews · 2019Pooled it
- Epidural therapy for the treatment of severe pre-eclampsia in non labouring women.The Cochrane database of systematic reviews · 2017Pooled it
- Antenatal interventions to reduce preterm birth: an overview of Cochrane Systematic Reviews.BMC research notes · 2014Pooled it
- Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy.BMC public health · 2011Pooled it
- Fetal Growth Restriction. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/080, October 2024).Geburtshilfe und Frauenheilkunde · 2025Article
- Evidence for hypoxia-induced dysregulated cholesterol homeostasis in preeclampsia: Insights into the mechanisms from human placental cells and tissues.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Physiology of Pregnancy-Related Acute Kidney Injury.Comprehensive Physiology · 2023Article
- The central role of natural killer cells in preeclampsia.Frontiers in immunology · 2023Review
- A Summary of Chinese Expert Consensus on Fetal Growth Restriction (An Update on the 2019 Version).Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2022Article
- 17-Hydroxyprogesterone caproate improves T cells and NK cells in response to placental ischemia; new mechanisms of action for an old drug.Pregnancy hypertension · 2020Article
- Therapeutic Potential of Regulatory T Cells in Preeclampsia-Opportunities and Challenges.Frontiers in immunology · 2019Review
- Gestational Hypoxia and Developmental Plasticity.Physiological reviews · 2018Review
- Continued Investigation Into 17-OHPC: Results From the Preclinical RUPP Rat Model of Preeclampsia.Hypertension (Dallas, Tex. : 1979) · 2017Article
- Intrauterine Growth Restriction. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015/080, October 2016).Geburtshilfe und Frauenheilkunde · 2017Article
- A Proposed Molecular Mechanism of High-Dose Vitamin D3 Supplementation in Prevention and Treatment of Preeclampsia.International journal of molecular sciences · 2015Article
- 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.Hypertension (Dallas, Tex. : 1979) · 2015Article
- Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemia.American journal of obstetrics and gynecology · 2013Article
- Prevention of preeclampsia.Journal of pregnancy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn the past, progesterone has been advocated for prevention of pre-eclampsia and its complications. Although progestogens are not used for this purpose in current clinical practice, it remains relevant to assess the evidence on their possible benefits and harms.
objectivesTo assess the effects of progesterone during pregnancy on the risk of developing pre-eclampsia and its complications. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (April 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library 2006, Issue 2), and EMBASE (1974 to August 2005). SELECTION CRITERIA: Randomised trials evaluating progesterone or any other progestogen during pregnancy for prevention of pre-eclampsia and its complications were included. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion and extracted data. MAIN
resultsTwo trials of uncertain quality were included (296 women). These trials compared progesterone injections with no progesterone. There was insufficient evidence to demonstrate any clear differences between the two groups on the risk of pre-eclampsia (one trial, 128 women; relative risk (RR) 0.21, 95% confidence interval (CI) 0.03 to 1.77), death of the baby (two trials, 296 women; RR 0.72, 95% CI 0.21 to 2.51), preterm birth (one trial, 168 women; RR 1.10, 95% CI 0.33 to 3.66), small-for-gestational-age babies (one trial, 168 women; RR 0.83, 95% CI 0.19 to 3.57) or major congenital defects (one trial, 168 women; RR 1.65, 95% CI 0.28 to 9.62). There were no reported cases of masculinisation of female babies (one trial, 128 women). Long-term follow up for the children has been reported in one trial, but the data are excluded from the review as 54% were lost to follow up at one year and 80% at 16 years. AUTHORS'
conclusionsThere is insufficient evidence for reliable conclusions about the effects of progesterone for preventing pre-eclampsia and its complications. Therefore, progesterone should not be used for this purpose in clinical practice at present. Unless new and plausible hypotheses emerge for the role of progesterone in development of pre-eclampsia, further trials of progesterone are unlikely to be a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.